Obstacles and future of gene therapy for hemophilia

Bibliography

• High KA. The gene therapy journey for hemophilia: are we there yet? Hematology Am Soc Hematol Educ Program 2012;2012:375-81
   PubMed Web of Science ®Google Scholar
• Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 2006;12(3):342-7
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Reiss UM, Tuddenham EG, et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 2014;371(21):1994-2004
   PubMed Web of Science ®Google Scholar
• Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011;365(25):2357-65
   PubMed Web of Science ®Google Scholar
• Skinner MW. WFH: closing the global gap--achieving optimal care. Haemophilia 2012;18(Suppl 4):1-12
   PubMed Web of Science ®Google Scholar
• Mingozzi F, High KA. Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 2011;12(5):341-55
   PubMed Web of Science ®Google Scholar
• Zinn E, Vandenberghe LH. Adeno-associated virus: fit to serve. Curr Opin Virol 2014;8:90-7
   PubMed Web of Science ®Google Scholar
• Gao GP, Alvira MR, Wang L, et al. Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci U S A 2002;99(18):11854-9
   PubMed Web of Science ®Google Scholar
• Maguire AM, Simonelli F, Pierce EA, et al. Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J Med 2008;358(21):2240-8
   PubMed Web of Science ®Google Scholar
• Gaudet D, Methot J, Dery S, et al. Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. Gene Ther 2013;20(4):361-9
   PubMed Web of Science ®Google Scholar
• Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010;17(3):295-304
   PubMed Web of Science ®Google Scholar
• Masat E, Pavani G, Mingozzi F. Humoral immunity to AAV vectors in gene therapy: challenges and potential solutions. Discov Med 2013;15(85):379-89
   PubMed Web of Science ®Google Scholar
• Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006;108(10):3321-8
   PubMed Web of Science ®Google Scholar
• Calcedo R, Wilson JM. Humoral immune response to AAV. Front Immunol 2013;4:341
   PubMed Web of Science ®Google Scholar
• Basner-Tschakarjan E, Mingozzi F. Cell-mediated immunity to AAV Vectors, evolving concepts and potential solutions. Front Immunol 2014;5:350
   PubMed Web of Science ®Google Scholar
• Li C, Narkbunnam N, Samulski RJ, et al. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Ther 2012;19(3):288-94
   PubMed Web of Science ®Google Scholar
• Wang L, Calcedo R, Bell P, et al. Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors. Hum Gene Ther 2011;22(11):1389-401
   PubMed Web of Science ®Google Scholar
• Monteilhet V, Saheb S, Boutin S, et al. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol Ther 2011;19(11):2084-91
   PubMed Web of Science ®Google Scholar
• Chicoine LG, Montgomery CL, Bremer WG, et al. Plasmapheresis eliminates the negative impact of AAV antibodies on microdystrophin gene expression following vascular delivery. Mol Ther 2014;22(2):338-47
   PubMed Web of Science ®Google Scholar
• Unzu C, Hervas-Stubbs S, Sampedro A, et al. Transient and intensive pharmacological immunosuppression fails to improve AAV-based liver gene transfer in non-human primates. J Transl Med 2012;10:122
   PubMedGoogle Scholar
• Corti M, Elder M, Falk D, et al. B-cell depletion is protective against Anti-AAV capsid immune response: A human subject case study. Mol Ther Methods Clin Dev 2014;10.1038/mtm.2014.33
   Google Scholar
• Calcedo R, Vandenberghe LH, Gao G, et al. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009;199(3):381-90
   PubMed Web of Science ®Google Scholar
• Allay JA, Sleep S, Long S, et al. Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 2011;22(5):595-604
   PubMed Web of Science ®Google Scholar
• Mingozzi F, Anguela XM, Pavani G, et al. Overcoming preexisting humoral immunity to AAV using capsid decoys. Sci Transl Med 2013;5(194):194ra92
   PubMed Web of Science ®Google Scholar
• Gao K, Li M, Zhong L, et al. Empty virions In AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side-effects. Mol Ther Methods Clin Dev 2014;1(9):20139
   Google Scholar
• Mimuro J, Mizukami H, Hishikawa S, et al. Minimizing the inhibitory effect of neutralizing antibody for efficient gene expression in the liver with adeno-associated virus 8 vectors. Mol Ther 2013;21(2):318-23
   PubMed Web of Science ®Google Scholar
• Raper SE, Wilson JM, Nunes FA. Flushing out antibodies to make AAV gene therapy available to more patients. Mol Ther 2013;21(2):269-71
   PubMed Web of Science ®Google Scholar
• Reddy SK, Kesmodel SB, Alexander HRJr. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol 2014;6(4):180-94
   PubMed Web of Science ®Google Scholar
• Arruda VR, Stedman HH, Haurigot V, et al. Peripheral transvenular delivery of adeno-associated viral vectors to skeletal muscle as a novel therapy for hemophilia B. Blood 2010;115(23):4678-88
   PubMed Web of Science ®Google Scholar
• Mingozzi F, Maus MV, Hui DJ, et al. CD8(+) T-cell responses to adeno-associated virus capsid in humans. Nat Med 2007;13(4):419-22
   PubMed Web of Science ®Google Scholar
• Flotte TR, Goetzmann J, Caridi J, et al. Apparently nonspecific enzyme elevations after portal vein delivery of recombinant adeno-associated virus serotype 2 vector in hepatitis C virus-infected chimpanzees. Hum Gene Ther 2008;19(7):681-9
   PubMed Web of Science ®Google Scholar
• Thomas CE, Storm TA, Huang Z, Kay MA. Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 2004;78(6):3110-22
   PubMed Web of Science ®Google Scholar
• Martino AT, Basner-Tschakarjan E, Markusic DM, et al. Engineered AAV vector minimizes in vivo targeting of transduced hepatocytes by capsid-specific CD8+ T cells. Blood 2013;121(12):2224-33
   PubMed Web of Science ®Google Scholar
• Martino AT, Suzuki M, Markusic DM, et al. The genome of self-complementary adeno-associated viral vectors increases toll-like receptor 9-dependent innate immune responses in the liver. Blood 2011;117(24):6459-68
   PubMed Web of Science ®Google Scholar
• Rogers GL, Suzuki M, Zolotukhin I, et al. Unique roles of TLR9- and MyD88-dependent and -independent pathways in adaptive immune responses to AAV-mediated gene transfer. J Innate Immun 2015;7(3):302-14
   PubMed Web of Science ®Google Scholar
• Zhu J, Huang X, Yang Y. The TLR9-MyD88 pathway is critical for adaptive immune responses to adeno-associated virus gene therapy vectors in mice. J Clin Invest 2009;119(8):2388-98
   PubMed Web of Science ®Google Scholar
• Wu TL, Li H, Faust SM, et al. CD8+ T cell recognition of epitopes within the capsid of adeno-associated virus 8-based gene transfer vectors depends on vectors’ genome. Mol Ther 2014;22(1):42-51
   PubMed Web of Science ®Google Scholar
• Faust SM, Bell P, Cutler BJ, et al. CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 2013;123(7):2994-3001
   PubMed Web of Science ®Google Scholar
• Simioni P, Tormene D, Tognin G, et al. X-linked thrombophilia with a mutant factor IX (factor IX Padua). N Engl J Med 2009;361(17):1671-5
   PubMed Web of Science ®Google Scholar
• Finn JD, Nichols TC, Svoronos N, et al. The efficacy and the risk of immunogenicity of FIX Padua (R338L) in hemophilia B dogs treated by AAV muscle gene therapy. Blood 2012;120(23):4521-3
   PubMed Web of Science ®Google Scholar
• Crudele JM, Finn JD, Siner JI, et al. AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 2015;125(10):1553-61
   PubMed Web of Science ®Google Scholar
• Monahan PE, Sun J, Gui T, et al. Employing a gain-of-function factor IX variant R338L to advance the efficacy and safety of hemophilia B human gene therapy: preclinical evaluation supporting an ongoing adeno-associated virus clinical trial. Hum Gene Ther 2015;26(2):69-81
   PubMed Web of Science ®Google Scholar
• Cantore A, Nair N, Della Valle P, et al. Hyperfunctional coagulation factor IX improves the efficacy of gene therapy in hemophilic mice. Blood 2012;120(23):4517-20
   PubMed Web of Science ®Google Scholar
• Monahan PE, Walsh CE, Powell JS, et al. Update on phase 1/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy for program for phemophilia B. J Thromb Haemost 2015;13(Suppl 2):87
   Google Scholar
• Chuah MK, Petrus I, De Bleser P, et al. Liver-specific transcriptional modules identified by genome-wide in silico analysis enable efficient gene therapy in mice and non-human primates. Mol Ther 2014;22(9):1605-13
   PubMed Web of Science ®Google Scholar
• Kotterman MA, Schaffer DV. Engineering adeno-associated viruses for clinical gene therapy. Nat Rev Genet 2014;15(7):445-51
   PubMed Web of Science ®Google Scholar
• Lisowski L, Dane AP, Chu K, et al. Selection and evaluation of clinically relevant AAV variants in a xenograft liver model. Nature 2014;506(7488):382-6
   PubMed Web of Science ®Google Scholar
• David AL, McIntosh J, Peebles DM, et al. Recombinant adeno-associated virus-mediated in utero gene transfer gives therapeutic transgene expression in the sheep. Hum Gene Ther 2011;22(4):419-26
   PubMed Web of Science ®Google Scholar
• Mattar CN, Nathwani AC, Waddington SN, et al. Stable human FIX expression after 0.9G intrauterine gene transfer of self-complementary adeno-associated viral vector 5 and 8 in macaques. Mol Ther 2011;19(11):1950-60
   PubMed Web of Science ®Google Scholar
• McCarty DM, Young SMJr, Samulski RJ. Integration of adeno-associated virus (AAV) and recombinant AAV vectors. Annu Rev Genet 2004;38:819-45
   PubMed Web of Science ®Google Scholar
• Chandler RJ, LaFave MC, Varshney GK, et al. Vector design influences hepatic genotoxicity after adeno-associated virus gene therapy. J Clin Invest 2015;125(2):870-80
   PubMed Web of Science ®Google Scholar
• Nichols T, Whitford MH, Arruda VR, et al. Translational data from AAV-mediated gene therapy of hemophilia B in dogs. Hum Gene Ther Clin Dev 2014. [Epub ahead of print]
   Google Scholar
• Buchlis G, Podsakoff GM, Radu A, et al. Factor IX expression in skeletal muscle of a severe hemophilia B patient 10 years after AAV-mediated gene transfer. Blood 2012;119(13):3038-41
   PubMed Web of Science ®Google Scholar
• Jiang H, Pierce GF, Ozelo MC, et al. Evidence of multiyear factor IX expression by AAV-mediated gene transfer to skeletal muscle in an individual with severe hemophilia B. Mol Ther 2006;14(3):452-5
   PubMed Web of Science ®Google Scholar
• Baltimore D, Berg P, Botchan M, et al. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science 2015;348(6230):36-8
   PubMed Web of Science ®Google Scholar
• Schuettrumpf J, Liu JH, Couto LB, et al. Inadvertent germline transmission of AAV2 vector: findings in a rabbit model correlate with those in a human clinical trial. Mol Ther 2006;13(6):1064-73
   PubMed Web of Science ®Google Scholar
• Favaro P, Downey HD, Zhou JS, et al. Host and vector-dependent effects on the risk of germline transmission of AAV vectors. Mole Ther 2009;17(6):1022-30
   PubMed Web of Science ®Google Scholar
• Favaro P, Finn JD, Siner JI, et al. Safety of liver gene transfer following peripheral intravascular delivery of adeno-associated virus (AAV)-5 and AAV-6 in a large animal model. Hum Gene Ther 2011;22(7):843-52
   PubMed Web of Science ®Google Scholar
• Manno CS, Chew AJ, Hutchison S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 2003;101(8):2963-72
   PubMed Web of Science ®Google Scholar
• Arruda VR, Hagstrom JN, Deitch J, et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. Blood 2001;97(1):130-8
   PubMed Web of Science ®Google Scholar
• Xu L, Gao C, Sands MS, et al. Neonatal or hepatocyte growth factor-potentiated adult gene therapy with a retroviral vector results in therapeutic levels of canine factor IX for hemophilia B. Blood 2003;101(10):3924-32
   PubMed Web of Science ®Google Scholar
• Xu L, Nichols TC, Sarkar R, et al. Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc Natl Acad Sci U S A 2005;102(17):6080-5
   PubMed Web of Science ®Google Scholar
• Cantore A, Ranzani M, Bartholomae CC, et al. Liver-directed lentiviral gene therapy in a dog model of hemophilia B. Sci Transl Med 2015;7(277):277ra28
   PubMed Web of Science ®Google Scholar
• Barzel A, Paulk NK, Shi Y, et al. Promoterless gene targeting without nucleases ameliorates haemophilia B in mice. Nature 2015;517(7534):360-4
   PubMed Web of Science ®Google Scholar
• Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl j Med 2003;348(3):255-6
   PubMed Web of Science ®Google Scholar
• Eckhardt CL, van Velzen AS, Peters M, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 2013;122(11):1954-62
   PubMed Web of Science ®Google Scholar
• DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007;138(3):305-15
   PubMed Web of Science ®Google Scholar
• Gouw SC, van den Berg HM, Oldenburg J, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012;119(12):2922-34
   PubMed Web of Science ®Google Scholar
• Warrier I, Ewenstein BM, Koerper MA, et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol 1997;19(1):23-7
   PubMed Web of Science ®Google Scholar
• Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1997;89(3):1115-16
   PubMed Web of Science ®Google Scholar
• Mingozzi F, Liu YL, Dobrzynski E, et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 2003;111(9):1347-56
   PubMed Web of Science ®Google Scholar
• Mount JD, Herzog RW, Tillson DM, et al. Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 2002;99(8):2670-6
   PubMed Web of Science ®Google Scholar
• Niemeyer GP, Herzog RW, Mount J, et al. Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 2009;113(4):797-806
   PubMed Web of Science ®Google Scholar
• Finn JD, Ozelo MC, Sabatino DE, et al. Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 2010;116(26):5842-8
   PubMed Web of Science ®Google Scholar
• Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, et al. Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 2007;110(7):2334-41
   PubMed Web of Science ®Google Scholar
• Soucie JM, Richardson LC, Evatt BL, et al. Risk factors for infection with HBV and HCV in a largecohort of hemophiliac males. Transfusion 2001;41(3):338-43
   PubMed Web of Science ®Google Scholar
• Doering CB, Spencer HT. Replacing bad (F)actors: hemophilia. Hematology Am Soc Hematol Educ Program 2014;2014(1):461-7
   PubMedGoogle Scholar
• Kuether EL, Schroeder JA, Fahs SA, et al. Lentivirus-mediated platelet gene therapy of murine hemophilia A with pre-existing anti-factor VIII immunity. J Thromb Haemost 2012;10(8):1570-80
   PubMed Web of Science ®Google Scholar
• Greene TK, Wang C, Hirsch JD, et al. In vivo efficacy of platelet-delivered, high specific activity factor VIII variants. Blood 2010;116(26):6114-22
   PubMed Web of Science ®Google Scholar
• Chen Y, Schroeder JA, Kuether EL, et al. Platelet gene therapy by lentiviral gene delivery to hematopoietic stem cells restores hemostasis and induces humoral immune tolerance in FIX(null) mice. Mol Ther 2014;22(1):169-77
   PubMed Web of Science ®Google Scholar
• Du LM, Nurden P, Nurden AT, et al. Platelet-targeted gene therapy with human factor VIII establishes haemostasis in dogs with haemophilia A. Nat Commun 2013;4:2773
   PubMed Web of Science ®Google Scholar
• Marder VJ, Aird WC, Bennett JS, et al. Hemostasis and thrombosis: basic principles and clinical practice. 6th edition. Lippincott Williams &Wilkins; Philadelphia: PA: 2013
   Google Scholar
• Lind P, Larsson K, Spira J, et al. Novel forms of B-domain-deleted recombinant factor VIII molecules. Construction and biochemical characterization. Eur J Biochem 1995;232(1):19-27
   PubMedGoogle Scholar
• Scallan CD, Liu T, Parker AE, et al. Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII. Blood 2003;102(12):3919-26
   PubMed Web of Science ®Google Scholar
• Pipe SW. Functional roles of the factor VIII B domain. Haemophilia 2009;15(6):1187-96
   PubMed Web of Science ®Google Scholar
• Fahs SA, Hille MT, Shi Q, et al. A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 2014;123(24):3706-13
   PubMed Web of Science ®Google Scholar
• Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D. Murine coagulation factor VIII is synthesized in endothelial cells. Blood 2014;123(24):3697-705
   PubMed Web of Science ®Google Scholar
• Siner. JI Iacobelli NP, Sabatino DE, Ivanciu L, Zhou S, Poncz M, et al. Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype. Blood 2013;121(21):4396-403
   Google Scholar
• Ward NJ, Buckley SM, Waddington SN, et al. Codon optimization of human factor VIII cDNAs leads to high-level expression. Blood 2011;117(3):798-807
   PubMed Web of Science ®Google Scholar
• McIntosh J, Lenting PJ, Rosales C, et al. Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant. Blood 2013;121(17):3335-44
   PubMed Web of Science ®Google Scholar
• Ide LM, Iwakoshi NN, Gangadharan B, et al. Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. J Gene Med 2010;12(4):333-44
   PubMed Web of Science ®Google Scholar
• Ide LM, Gangadharan B, Chiang KY, et al. Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 2007;110(8):2855-63
   PubMed Web of Science ®Google Scholar
• Greene TK, Lyde RB, Bailey SC, et al. Apoptotic effects of platelet factor VIII on megakaryopoiesis: implications for a modified human FVIII for platelet-based gene therapy. J Thromb Haemost 2014;12(12):2102-12
   PubMed Web of Science ®Google Scholar
• Ozelo MC, Vidal B, Brown C, et al. Omental implantation of BOECs in hemophilia dogs results in circulating FVIII antigen and a complex immune response. Blood 2014;123(26):4045-53
   PubMed Web of Science ®Google Scholar
• Hay CR, DiMichele DM. International Immune Tolerance Study. The principal results of the international immune tolerance study: a randomized dose comparison. Blood 2012;119(6):1335-44
   PubMed Web of Science ®Google Scholar
• Bryant LM, Christopher DM, Giles AR, et al. Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 2013;24(2):55-64
   PubMed Web of Science ®Google Scholar
• Kotin RM. Large-scale recombinant adeno-associated virus production. Hum Mol Genet 2011;20(R1):R2-6
   PubMedGoogle Scholar
• Hastie E, Samulski RJ. AAV at 50: a golden anniversary of discovery, research, and gene therapy success, a personal perspective. Hum Gene Ther 2015;26(5):257-65
   PubMed Web of Science ®Google Scholar
• Wright JF. Adeno-associated viral vector manufacturing: keeping pace with accelerating clinical development. Hum Gene Ther 2011;22(8):913-14
   PubMed Web of Science ®Google Scholar
• Ayuso E, Blouin V, Lock M, et al. Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther 2014;25(11):977-87
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood 2007;110(3):815-25
   PubMed Web of Science ®Google Scholar
• Plug I, Peters M, Mauser-Bunschoten EP, et al. Social participation of patients with hemophilia in the Netherlands. Blood 2008;111(4):1811-15
   PubMed Web of Science ®Google Scholar
• Hough C, Lillicrap D. Gene therapy for hemophilia: an imperative to succeed. J Thromb Haemost 2005;3(6):1195-205
   PubMed Web of Science ®Google Scholar
• Powell JS. Lasting power of new clotting proteins. Hematology Am Soc Hematol Educ Program 2014;2014(1):355-63
   PubMedGoogle Scholar
• George LA, Camire RM. Profile of efraloctocog alfa and its potential in the treatment of hemophilia A. J Blood Med 2015;6:131-41
   PubMedGoogle Scholar